S.A. RYABOVA¹, A.V. PRIKHOD’KO¹, Y.V. TEZIKOV¹, I.S. LIPATOV¹, N.A. KRASNOVA¹, O.B. KALINKINA¹, L.N. KHUDYAKOVA²

¹Samara State Medical University, 89 Chapayevskaya Str., Samara, Russian Federation, 443099

²Samara Regional Clinical Hospital named after V.D. Seredavin, 159 Tashkentskaya Str., Samara, Russian Federation, 443095

Ryabova S.A. — post-graduate student of the Department of Obstetrics and Gynecology No 1, tel. +7-937-203-89-84, e-mail: svetliachok1988@ramble.ru

Prikhod’ko A.V. — post-graduate student of the Department of Obstetrics and Gynecology No. 1, tel. +7-927-764-36-58, e-mail: taura1991@mail.ru

Tezikov Yu.V. — D. Med. Sc., Professor, Head of the Department of Obstetrics and Gynecology No. 1, tel. +7-927-685-44-85, e-mail:yra.75@inbox.ru

Lipatov I.S. — Doctor of Medical Sciences, Professor of the Department of Obstetrics and Gynecology No. 1, tel. +7-927-262-92-70, e-mail:i.lipatoff2012@yandex.ru

Krasnova N.A. — Cand. Med. Sc., Associate Professor of the Department of Obstetrics and Gynecology No 1, tel. +7-902-372-97-52, e-mail:alexander-krasnov@mail.ru

Kalinkina O.B. — D. Med. Sc., Professor of the Department of Obstetrics and Gynecology No. 1, tel. +7-927-608-08-72, e-mail: maiorof@mail.ru

Khudyakova L.N. — obstetrician-gynecologist of the highest qualification category, tel. +7-927-60-80-82,e-mail: maiorof@mail.ru

 Comparison was made of the effectiveness of various therapy schemes with itraconazole in patients of reproductive age with a recurrent form of vulvovaginal candidiasis. It has been shown that taking the drug for 4 days (8 capsules = 800 mg of itraraconazole) is more effective than a 3-day course of treatment (3 capsules = 600 mg of itraconazole) and no less effective than a 5-day course of therapy (10 capsules = 1000 mg of itraraconazole). The obtained data are proved by the standards of efficiency of probative medicine.

Key words: vulvovaginal candidiasis; therapy; Itraconazole; efficiency, probative medicine.

REFERENCES

1. Kulakov V.I., Saveleva G.M., Manukhin I.B. Gynecology. National leadership, 2011. 1072 p.
2. Mirzabalayeva A.K. Candidiasis of the genitals in obstetrical and gynecological practice. Status praesens, 2011, No. 2, pp. 57-60.
3. Solovyov A.V., Plaksina N.D., Silvestrov G.A., Radzinsky V.E. Vulvovaginal candidiasis: how to avoid relapse. Clinical lecture. Editorial Office of the journal Status Praesens, 2013, 16 p.
4. Ogouyèmi-Hounto A., Adisso S., Djamal J. еt al. Place of vulvovaginal candidiasis in the lower genital tract infections and associated risk factors among women in Benin. J Mycol Med, 2014, № 24(2), pp.100-5.
5. Gonçalves B., Ferreira C., Alves C.T. еt al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol, 2015, № 21, pp. 1-23.
6. Kalinkina O.B., Tezikov Yu.V., Lipatov I.S., Arabina O.R. Influence of obesity on the reproductive health of a woman. Postgraduate Bulletin of the Volga Region, 2016, № 5-6, pp. 55-61.
7. Baykushev R., Ouzounova-Raykova V., Stoykova V., Mitov I. Reliable microbiological diagnosis of vulvovaginal candidiasis. Akush Ginekol (Sofiia), 2014, pp. 17-20.
8. Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG, 2015, May, pp. 785-94.
9. Kotelnikov G.P., Shpigel A.S. Evidence-based medicine. Scientifically based medical practice: monograph, 2012. 242 p.